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Background: Patients with ulcerative colitis (UC) are treated with prednisolone (PSL), which causes adverse side
effects. Extracorporeal granulocyte/monocyte adsorption (GMA) with an Adacolumn depletes elevated/activated
myeloid lineage leucocytes as sources of inflammatory cytokines. We were interested to evaluate the efficacy, safety
and the treatment cost for PSL and GMA.
Methods: Forty-one patients with active UC had achieved remission with GMA, at 1 or 2 sessions/week, up to 10
sessions (n=24) or with orally administered PSL (1mg/kg bodyweight, n=17). Clinical activity index (CAI) ≤4 was
considered clinical remission. Following remission, patients received 5-aminosalicylic acid (2250-3000mg/day) or
sulphasalazine (4000-6000mg/day) as maintenance therapy and were followed for 600 days. The total treatment
cost was assessed based on 1€=150JPY.
Results: PSL was tapered after two weeks, and discontinued when a patient achieved remission. The average time
to the disappearance of at least one major UC symptom (haematochezia, diarrhoea, or abdominal discomfort) was
15.3 days in the GMA group and 12.7 days in the PSL group, while time to remission was 27.9 days in the GMA
group and 27.6 days in the PSL group, CAI 0.8 and 2.0, respectively. The Kaplan-Meier plots showed similar
remission maintenance rates over the 600 days follow-up period. The average medical cost was 12739.4€/patient in
the GMA group and 8751.3€ in the PSL group (P<0.05). In the GMA group, 5 transient adverse events were
observed vs 10 steroid related adverse events in the PSL group (P<0.001).
Conclusions: In appropriately selected patients, GMA has significant efficacy with no safety concern. The higher
cost of GMA vs PSL should be compromised by good safety profile of this non-pharmacological treatment
intervention.
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Treatment safetyBackground
Ulcerative colitis (UC) is one of the two major phenotypes
of the chronic inflammatory bowel disease (IBD); the
other major phenotype of IBD is Crohn’s disease [1,2]. UC
afflicts millions of individuals throughout the world, caus-
ing symptoms like fever, weight loss, diarrhoea, rectal
bleeding and abdominal discomfort, which impair individ-
ual’s activities and quality of life. Currently, there is no
permanent cure for UC, the treatments focus on* Correspondence: tominaga@dokkyomed.ac.jp
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reproduction in any medium, provided the orcontrolling the disease activity with pharmacologics, often
at high doses over long periods of time [1,3,4]. Corticoste-
roids like prednisolone (PSL) have had a major role in the
treatment of UC since the pioneering trials by Truelove,
and colleagues several decades ago [5,6]. However, when
used in chronic, remitting-relapsing conditions like UC,
corticosteroids cause adverse side effects, steroid depend-
ency and refractoriness [1,3]. It is known that long-term
administration of corticosteroids potentially increases the
development of osteoporosis, and cataracts as adverse side
effects, which are more likely at higher corticosteroid
doses [7-9]. Accordingly, in one major study, the incidenceral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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group as compared with the low dose group [9].
There is evolving evidence for myeloid lineage
leucocytes (granulocytes and monocytes) as major fac-
tors in the immunopathogenesis of UC. Thus, patients
with UC may harbour elevated peripheral neutrophils
[10] in the presence of compromised lymphocytes
[11-13]. Further, in UC, neutrophils show activation be-
havior [14] and prolonged survival [15]. Factors known
to promote neutrophil survival include inflammatory cy-
tokines [16], and paradoxically corticosteroids [17]. In-
deed, neutrophil activation and prolonged survival is a
feature of persistent intestinal inflammation and histo-
logical examinations of the mucosal tissue in biopsy
specimens from patients with active UC reveals a
spectrum of pathologic manifestations among which
presence of neutrophils accounts not only for the mor-
phologic lesions of UC, but also for the prevailing pat-
terns of mucosal inflammation [1,14,15,18]. When
activated, granulocytes together with monocytes/macro-
phages produce an array of pleiotropic cytokines like
tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-
6, IL-12, IL-23 which are strongly inflammatory [19-23].
These have given rise to the inference that elevated and
activated granulocytes and monocytes should be targets
of therapy in UC. Based on theses observations, the
Adacolumn has been developed for selective depletion
of granulocytes and monocytes by adsorption (GMA).
In the early 2000, following a major multicentre clin-
ical trial [24,25], GMA was introduced into the Japan
national health reimbursement scheme as remission in-
duction therapy for patients with UC. Subsequently, in-
vestigators reported high remission rates and good safety
profile for GMA [26-30], but disappointing trial out-
comes have been reported as well [31]. In this study, we
aimed to assess the efficacy, safety and treatment cost in
two cohorts of patients with active UC treated with
GMA or with PSL as remission induction therapy.
Methods
Patients
The subjects were 41 patients with UC in the active
stage who had been successfully treated by GMA as re-
mission induction therapy in the period from April 2000
to March 2009 at our hospital (GMA group, n=24) or
with the corticosteroid, prednisolone (PSL group, n=17).
The demographic features of the included patients are
presented in Table 1. These 41 patients were retrospect-
ively reviewed. The patients were from two bigger co-
horts, 43 and 24, respectively who had responded to
these interventions. The remaining patients (19 and 7)
either had not achieved remission or were not eligible
for this follow-up study (receiving additional medica-
tions was one exclusion criterion). Following remissioninduction, patients were given 5-aminosalicylic acid
(5-ASA, 2250-3000mg/day) or sulphasalazine (4000-
6000mg/day) as maintenance therapy. If a patient had
been on azathioprine (AZA) for >8 weeks prior to the
start of the present therapy (GMA or PSL), the patient
could be included and AZA was to be continued at the
same dosage if required (Table 1). PSL dose was to be ta-
pered within two weeks following the start of adminis-
tration and subsequently discontinued when patient
achieved remission.
Adsorptive depletion of myeloid lineage leucocytes
Adsorptive depletion of myeloid lineage leucocytes
(GMA) was done with the Adacolumn as previously de-
scribed [10,12,13,28]. The Adacolumn is filled with cel-
lulose acetate beads of 2mm in diameter as the column
adsorptive leucocytapheresis carriers [32,33]. The car-
riers adsorb from the blood in the column most of the
granulocytes and monocytes together with a significant
fraction of platelets (FcγR and complement receptor
bearing cells); lymphocytes are spared. In fact lympho-
cytes increase after GMA [12,13,32,33], including the
CD4+CD25high+ phenotype, which is known as a key
regulator of immune function [33,34]. Each patient re-
ceived 1 or 2 GMA sessions/week, up to 10 sessions.
One session was 60–90 min at 30mL/min [28].
Treatment of patients in the PSL group
In the PSL group, patients received PSL orally, at 1mg/kg
(bodyweight)/day orally as the starting dose. The PSL dose
was to be tapered at 5 to 10 mg per week within 2 weeks
following initiation of therapy. Following remission, PSL
could be discontinued and replaced with maintenance
therapy, 5-ASA or sulphasalazine (indicated above).
Assessment of disease activity and treatment efficacy
UC clinical activity index (CAI) was determined at entry
and at appropriate time points during active treatment
and the 24 months follow-up period according to
Rachmilewitz [35]. Factors considered in the present
study for assessing efficacy were blood in the stool, diar-
rhoea and abdominal pain as major complication of UC
that most seriously impact activities and quality of life
[1,2]. The time to the cessation of at least one major UC
symptom as well as the time to remission (CAI ≤4) was
used to assess the immediate efficacy of the treatments,
while the long-term effect on UC activity was assessed
by the Kaplan-Meier survival graphs. The cumulative
dose of PSL, average treatment cost per patient were
also determined.
Ethical considerations
In Japan, GMA with the Adacolumn is an officially ap-
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Figure 1 This figure shows time to the disappearance of at
least one major ulcerative colitis (UC) symptoms (diarrhoea,
rectal bleeding, and abdominal discomfort) as well as time to
remission (clinical activity index, CAI≤4) following the start of
interventions. As shown, no statistically significant (ns) difference
between the patients who received the corticosteroid, PSL and
those who received the non-pharmacologic, GMA was found.
Table 1 Entry demography of the 41 patients of this study
GMA PSL
Gender: Male/Female 14/10 7/10
Mean age (range) 33.6(15–78) 35.4(13–65)
Extent of UC Total 17 10
Left sided 6 5
Recto-sigmoid 1 2
Clinical course Chronic continuous type 0 1
Relapsing remitting type 28 14
First UC episode 0 2
Inpatient/Outpatient 19/5 17/0
Patients with a history of exposure to PSL 17 13
Patients on AZA (50mg/day) 8 8
GMA, adsorptive granulocyte and monocyte apheresis; PSL, predonisolone; AZA, azathioprine (started ≥8 weeks ahead of entry).
All patients were included following a relapse of ulcerative colitis (UC)
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patients after explaining the study aim and the nature of
the procedures involved. Adherence was made to the
Principle of Good Clinical Practice and the Declaration
of Helsinki at all times.
Statistical analysis
Where appropriate, data are presented as the mean ±
SD values. The differences between sets of parametric
data were analyzed by using the t-statistic. The relapse
rate was estimated by the Kaplan-Meier survival graphs
and the log-rank test. P<0.05 was considered significant.
Results
Time to the disappearance of at least one major UC
symptom and clinical remission
Figure 1 shows time to the disappearance of at least one
major UC complication like diarrhoea, haematochezia or
abdominal discomfort as well as time to remission (CAI
≤4) in the two groups following start of interventions
(GMA and PSL). As shown, no statistically significant
difference between the patients who received PSL and
those who received the non-pharmacologic, GMA was
found. The average time to the cessation of at least one
major UC complication was 15.6 ± 15.2 days in the
GMA group and 12.7 ± 12.9 days in the PSL group.
Likewise, the average time to clinical remission was 27.9
± 19.6 days in the GMA group and 27.6 ± 29.0 days in
the PSL group.
Efficacy outcomes based on CAI
The outcomes of the efficacy assessment based on CAI
is presented in Figure 2, essentially echoing the out-
comes seen in Figure 1. The average CAI value when at
least one of the major complications of UC disappeared
was 4.3 ± 2.9 in the GMA group and 6.7 ± 3.4 in thePSL group indicating that at this time point, clinical re-
mission was not achieved by all patients. Instead, the
CAI value was significantly reduced in both groups rela-
tive to active disease, but without any significant differ-
ence between the two groups. Similarly, the average CAI
value when the patients achieved remission was 0.8 ±
1.3 in the GMA group and 2.0 ± 2.2 in the PSL group,
without significant difference between the GAM and the
PSL groups.
The Kaplan-Meier graphs of remission maintenance
Figure 3 shows the Kaplan-Meier survival graphs of re-
mission maintenance during a 600 day follow-up obser-
vation at the end of active treatment. As shown, the rate
























Figure 2 Overall improvements in the clinical activity indices
(CAI) in two groups of patients with active UC receiving GMA
or PSL. This figure shows average CAI values at baseline, at the time
point when major UC symptoms were reduced and when patients
achieved remission. No significant (ns) difference between the
patients who received PSL and those who received the non-
pharmacologic intervention, GMA was found.
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GMA and the PSL groups.
The cumulative dose of corticosteroid in the GMA and the
PSL groups
From patients’ case records, we could calculate the total
amount of corticosteroid patients had received for the
duration of UC in either group. Corticosteroid was PSL
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Figure 3 The Kaplan-Meier plots showing maintenance of
remission in two groups of patients receiving GMA or PSL.
Patients who achieved remission (CAI≤4) at the end of the active
treatment period (arrow head) were followed to monitor
maintenance of remission. As shown, no significant (ns) difference
between the two groups was found with respect to maintenance of
clinical remission at the end of the follow-up time (600 days).PSL before the start of the present investigation was
2556.8mg in the GMA group and 3030.4mg in the PSL
group, not significantly different (Table 2). The cumula-
tive amount of PSL during the present study was 0mg in
the GMA group and 1122.4mg in the PSL group
(P<0.001). All patients in the GMA group were steroid
naïve for that flare up.
Adverse events and treatment cost
Figure 4 shows the outcomes of the adverse event assess-
ment, and medical costs (1€ = 150JPY) in the two groups
of patients with UC who received GMA or PSL as a treat-
ment intervention. Five adverse events in 3 of 24 patients
(12.5%) were reported in the GMA group. These were
transient fever, dizziness and light headedness developed
towards the end of a GMA session. These events remitted
within 3 h without any medication. In the PSL group, 6 of
17 patients (35.3%) developed corticosteroid related
adverse events, total 10 events including steroid acne in
2 patients, mild liver disorder in 2 patients, moon face
in 2 patients; osteoporosis in 1 patient and Candida
oesophagitis in 1 patient Additionally two patients (11.8%)
in the PSL group developed nausea just after the adminis-
tration of PSL. The latter two events resolved within a few
hours similar to the events in the GMA group. Regarding
the treatment cost in the present investigation, our calcu-
lation showed an average cost of 12739.4€ per patient for
GMA and 8751.3€ per patient for PSL (P<0.05).
Discussion
The major focus of this study was on the safety, efficacy,
and the medication cost analyses in patients with active
UC being treated by GMA as a non-pharmacologic
intervention (GMA group) or with the corticosteroid,
PSL (PSL group). All included patients had already
achieved remission following these interventions and
were reviewed retrospectively. This was possible for the
fact that all patients were registered at our hospital and
had been treated by the physicians who are the authors
of this article. Further, for the analyses we undertook in
this study, patients who had achieved remission were in-
cluded to allow us to see the sustainability of remission
achieved with these two interventions. The outcomes
might be summarised as follows. As the first treatment
end point, we considered UC symptoms, which patients
consider as the most serious cause of impaired activities
and quality of life. These included diarrhoea, rectal
bleeding, and abdominal discomfort. The average time
to the cessation of at least one of these symptoms was
not significantly different between the patients who re-
ceived PSL and those who received GMA. The second
treatment end point we considered was clinical remis-
sion. Similar to the first end point, the average time to
remission was not significantly different between the
Table 2 Outcomes of the cost analyses for two groups of patients receiving adsorptive granulocyte and monocyte
apheresis (GMA) or prednisolone (PSL) at the end of the study (average values are presented)
Factored item GMA PSL P value
Days of hospitalization 41.1 41.8 ns
(n=19) (n=17)
Hospitalization cost (euro)* 12739.4 8633.6 P<0.05
(n=19) (n=17)
Cumulative dose of PSL before the treatment (mg) 2457.9 3030.4 ns
(n=24) (n=17)
Concomitant dose of PSL during this study (mg) 0 (naïve) 1122.4 P<0.001
(n=24) (n=17)
Cumulative dose of PSL up to the end of study (mg) 2457.9 4152.8 P=0.28
(n=24) (n=17)
Adverse event (%)
Transient 12.5 11.8 ns
Non-transient 0 35.3 P<0.001
* Converted at 150 yen to the euro. Hospitalization cost includes treatment cost, medication, tests.
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CAI reflected the outcomes we monitored as time to the
cessation of major UC symptoms and UC remission.
The sustainability of remission was another significant
consideration in this study. To see this, we applied the
Kaplan-Meier survival analysis of remission maintenance
during a 600 day follow-up. The rate of relapse was not
significantly different between the two groups.
Regarding the cumulative amount of PSL, in the GMA
group, patients had relapsed while not being on a cortico-
steroid (were steroid naïve for that relapse). These patients
received GMA as the only medication for that flare up ex-
























Figure 4 Assessment of adverse events, medical costs (1€ = 150JPY) a
patients with active ulcerative colitis (UC) who received GMA or PSL a
safety over PSL, while the treatment cost is in favour of PSL.well in advance of receiving GMA. Nonetheless, we calcu-
lated the total amount of PSL patients in the two groups
had received for the duration of UC disease. Our calcula-
tions did not show any significant difference in the
amount of corticosteroid patients had received before the
start of the medications factored into this investigation
(GMA and PSL). This was because, like the patients in the
GMA group, patients in the PSL group had relapsed while
not being on a corticosteroid. Further, for this investiga-
tion, we ensured that all patients in the GMA group re-
main corticosteroid free during the follow-up time as well
and in the PSL group, the dose of PSL was tapered when
patients improve and discontinued when patients achievedPSL














nd the cumulative dose of prednisolone (PSL) in two groups of
s a treatment intervention. This figure shows GMA has favourable
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during the present study was 0mg in the GMA group and
1122.4 mg per patient in the PSL group, clearly showing
that GMA spares patients from corticosteroids. Similarly,
our safety evaluation showed the data to be very much in
favour of GMA with just a few transient and non-serious
adverse side effects, which is in line with earlier reports on
the safety of GMA in patients with UC [10,12,25-33]. In
contrast, over 40% of patients in the PSL group developed
adverse events. However our figures from the calculations
of the medication cost was in favour of PSL as this is a
relatively inexpensive medication as compared with the
single use Adacolumns required for GMA. Our impres-
sion is that this cost difference is more than offset by the
safety of GMA [36].
Following the publication of the first clinical trial of
GMA in patients with UC [24], several investigators
from Japan, Europe, and the USA [12,27-30,37-43], have
reported varying efficacy outcomes ranging from an im-
pressive 85% [12] to a statistically insignificant level [31]
Except [31,37,38,41], most other studies did not include
a control arm, relying on patients’ disease activity at
baseline to serve as a control parameter to judge treat-
ment efficacy [12,27-30]. Among controlled studies,
Maiden et al., used GMA to suppress clinical relapse in
one arm, while the control arm received no treatment
[14]. At the end of a 6-month follow-up, both the re-
lapse rate and time to clinical relapse were significantly
better in the GMA arm [14]. Further, intensive GMA in-
volving two sessions per week was found to be more ef-
fective than the routinely applied weekly GMA sessions
[44]. Likewise, there are reports saying that patients with
deep colonic lesions and extensive loss of the mucosal
tissue at the lesion sites show very poor response to
GMA [12,29,43], while first episode and steroid naïve
cases respond well and avoid corticosteroids [12,29,39].
Conclusions
The results of this study showed that GMA as a non-
pharmacologic treatment intervention in patients with
UC produced efficacy equivalent to the corticosteroid,
PSL and was without safety concern. In view of serious
adverse side effects associated with long-term adminis-
tration of drugs, GMA is very much favoured by patients
for its safety profile. In particular, young and elderly pa-
tients should benefit most from GMA as a replacement
for corticosteroids and other potentially unsafe medica-
tions including biologics. However, the results of this
study require further support by a prospective controlled
study in large cohorts of patients.
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